Company Name
Enliven Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US29337E1029
CIK:
0001672619
CUSIP:
29337E102
Currency:
USD
Full Time Employees:
65
Phone:
720 647 8519
Website:
https://www.enliventherapeutics.com
Fiscal Year End:
December
IPO Date:
Mar 12, 2020
Description:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Address:
6200 Lookout Road, Boulder, CO, United States, 80301